Trial reportSports medicine (Auckland, N.Z.)2016
Sub-anesthetic Xenon Increases Erythropoietin Levels in Humans: A Randomized Controlled Trial.
Trial report in Sports medicine (Auckland, N.Z.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 33 citations in OpenAlex.
- Xenon postconditioning attenuates neuronal injury after spinal cord ischemia/reperfusion injury by targeting endoplasmic reticulum stress-associated apoptosis.Neurosurgical review · 2023Article
- Are Protein Cavities and Pockets Commonly Used by Redox Active Signalling Molecules?Plants (Basel, Switzerland) · 2023Review
- Effect of xenon and argon inhalation on erythropoiesis and steroidogenesis: A systematic review.Heliyon · 2023Review
- Xenon treatment after severe traumatic brain injury improves locomotor outcome, reduces acute neuronal loss and enhances early beneficial neuroinflammation: a randomized, blinded, controlled animal study.Critical care (London, England) · 2020Article
- Update of the organoprotective properties of xenon and argon: from bench to beside.Intensive care medicine experimental · 2020Review
- Neuroprotective Properties of Xenon.Molecular neurobiology · 2020Review
- Review of WADA Prohibited Substances: Limited Evidence for Performance-Enhancing Effects.Sports medicine (Auckland, N.Z.) · 2019Review
- Authors' Reply to Anoop Balachandran et al.: Comment on "Sub-Anesthetic Xenon Increases Erythropoietin Levels in Humans: A Randomized Controlled Trial".Sports medicine (Auckland, N.Z.) · 2017Article
- Comment on "Sub-anesthetic Xenon Increases Erythropoietin Levels in Humans: A Randomized Controlled Trial".Sports medicine (Auckland, N.Z.) · 2017Article
- Charting a course for erythropoietin in traumatic brain injury.Journal of translational science · 2016Article
- Erythropoietin and mTOR: A "One-Two Punch" for Aging-Related Disorders Accompanied by Enhanced Life Expectancy.Current neurovascular research · 2016Review
- Evidence that gaseous anesthesia may be due to neuronal hypoxia.Medical gas researchArticle
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe licensed anesthetic xenon, which exerts organ protective properties, was recently added by the World Anti-Doping Agency to the list of prohibited substances. Xenon is supposed to trigger the production of hypoxia-inducible factor 1α (HIF-1α) and subsequently erythropoietin, but data are limited to in vivo experimental work. Therefore we evaluated the effect of xenon on erythropoietin levels in healthy persons.
methodsTwenty-four healthy volunteers were randomly assigned either to a group spontaneously breathing xenon 30 % (Xe/O
resultsThe administration of xenon significantly increased erythropoietin levels 8 h after exposure (1.34 [±0.368]; p = 0.008), peaking at 24 h compared to the baseline values (1.45 [±0.498]; p = 0.01) and remained traceable in blood and exhalation probes until 24 h after exposure. In contrast, no significant change was observed in the control group. Measurement of stromal cell-derived factor 1 (SDF-1) revealed a significant increase of SDF-1 levels (p = 0.005), whereas no differences were observed with respect to growth factors, cytokines, or androgens. In an in vitro chemotaxis assay, endothelial progenitor cells (EPCs) showed a trend towards increased migration in serum samples received from participants after xenon exposure (p = 0.080).
conclusionThe present study presents first evidence about a xenon-induced effect on increased erythropoietin levels in healthy volunteers. The study was registered at the European Medicines Agency (EudraCT-number: 2014-000973-38) and at ClinicalTrials.gov (NCT number: 02129400).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.